intact animal to the cellular, subcellular, and molecular levels. It is published 12 times a year (monthly) by the American lymphatics, including experimental and theoretical studies of cardiovascular function at all levels of organization ranging from the publishes original investigations on the physiology of the heart, blood vessels, and AJP -Heart and Circulatory Physiology ϩ (KDR) current and limit agonist-induced depolarization and constriction. Smooth muscle cells from rat cerebral arteries were enzymatically isolated, and whole cell K DR currents were monitored with conventional patch-clamp electrophysiology. The K DR current averaged 21.2 Ϯ 2.3 pA/pF (mean Ϯ SE) at ϩ40 mV and was potently inhibited by UTP. Current suppression was eliminated in the presence of C3 exoenzyme, confirming that this modulation is dependent on RhoA. Activation of PKA (dibutyryl-cAMP, forskolin) or PKG (dibutyryl-cGMP, sodium nitroprusside, nitric oxide) similarly abolished the ability of UTP to suppress K DR and did so without effect on baseline current. Using pressure myography techniques, we stripped cerebral arteries of endothelium and preconstricted them with UTP; these were subsequently shown to hyperpolarize and dilate to both forskolin and sodium nitroprusside. An increase in K V channel activity was found to partly underlie these associated changes, as constriction to 4-aminopyridine (K DR channel blocker) was greater after PKA or PKG activation. We conclude from our electrophysiological and functional observations that the PKA and PKG pathways attenuate the ability of UTP to depolarize and constrict cerebral arteries in part by minimizing the RhoA-mediated suppression of the K DR current.
AN INTEGRATED NETWORK OF RESISTANCE arteries effectively controls blood flow to the cerebral circulation. Under dynamic conditions, arterial tone is regulated by a variety of factors, including metabolism (11) , humoral and neural stimuli (28) , blood flow (8) , and intraluminal pressure (12, 16) . Many vasoactive stimuli initiate changes in arterial tone by activating transduction pathways associated with G-protein-coupled receptors. It is key proteins within such pathways that in turn influence the Ca 2ϩ sensitivity of the myofilament (29) and/or ion channels that control cytosolic Ca 2ϩ through changes in resting membrane potential (E m ) (20) .
The Rho pathway is a primary signaling cascade controlling smooth muscle contraction. The key molecular switch within this pathway is RhoA, a small GTPase typically activated by receptors coupled to G 12/13 and Rho guanine nucleotide exchange factors (4, 25, 30) . In the active GTP-bound state, RhoA is targeted to the sarcolemma (10) where it associates with its principal downstream effector, Rho kinase (31) . Activated Rho kinase in turns inhibits myosin light-chain phosphatase, increasing the phosphorylation state of myosin and the contractile response to available Ca 2ϩ (31) . In addition to sensitizing the contractile apparatus, recent studies have indicated that RhoA signaling plays an important role in modulating ion channels (9, 18) . This includes the inhibition of the delayed rectifying K ϩ (K DR ) current, a response that enables agonists such as UTP to depolarize and constrict intact cerebral arteries (18) .
Recent investigations have noted that RhoA signaling is strongly influenced by the activity of protein kinase A (PKA) and G (PKG). In particular, these kinases have been reported to phosphorylate active, membrane-bound RhoA and to promote protein translocation to the cytosol (6, 17, 19, 24, 26) . Without membrane localization, it is difficult for RhoA to activate downstream effectors such as Rho kinase. Smooth muscle relaxation typically ensues, and most studies have ascribed this functional effect to reduced Ca 2ϩ sensitization (19, 24) . Although Ca 2ϩ sensitization is important, one should not overlook the possibility that PKA and PKG may also promote smooth muscle relaxation by limiting the ability of active RhoA to inhibit K DR channels and depolarize vascular smooth muscle.
In this study, we examined whether the activation of the PKA and PKG pathways would attenuate the ability of RhoA to inhibit K DR channels and to depolarize and constrict intact cerebral arteries. Initial measurements revealed the presence of a K DR current in cerebral arterial smooth muscle cells; this current was potently inhibited by UTP through a RhoA-dependent mechanism. Activators of PKA and PKG impeded the ability of UTP to inhibit the K DR current without affecting baseline channel activity. Functional experiments demonstrated that PKA and PKG activators hyperpolarized and dilated UTP-constricted cerebral arteries, a response that could be partly ascribed to the increased activity of 4-aminopyridine (4-AP)-sensitive K DR channels. In summary, our findings reveal a novel regulatory mechanism in the cerebral circulation, whereby PKA and PKG pathways limit RhoA-dependent suppression of the 4-AP-sensitive K DR current. This mechanism may be essential in preventing agonists from overly constricting cerebral arteries and impairing tissue blood flow.
MATERIALS AND METHODS
Animal procedures and tissue preparation. All animal procedures were approved by the University of Calgary Animal Care and Use Committee. In brief, female Sprague-Dawley rats (10 -12 wk of age) were euthanized by carbon dioxide asphyxiation. The brain was carefully removed and placed in cold PBS (pH 7.4) solution containing (in mM) 138 NaCl, 3 KCl, 10 Na 2HPO4, 2 NaH2PO4, 5 glucose, 0.1 CaCl2, and 0.1 MgSO4. Middle cerebral arteries were carefully dissected free of connective tissue and cut into ϳ2-mm segments.
Isolation of arterial smooth muscle cells. Smooth muscle cells from cerebral arteries were enzymatically isolated as previously described (32) . Briefly, segments of cerebral arteries were placed in an isolation medium containing (in mM) 60 NaCl, 80 sodium glutamate, 5 KCl, 2 MgCl 2, 10 glucose, and 10 HEPES with 1 mg/ml albumin (pH 7.4). After a 10-min equilibration at 37°C, the tissue was incubated for 15 min in the same medium supplemented with 0.5 mg/ml papain and 1.5 mg/ml DTT. This was followed by 10-min incubation in isolation medium containing 100 M Ca 2ϩ , 0.7 mg/ml type F collagenase, and 0.4 mg/ml type H collagenase. After enzyme treatment, the tissue was washed repeatedly in ice-cold isolation medium and triturated with a fire-polished pipette to liberate myocytes. Isolated cells were kept in ice-cold isolation medium for use the same day.
Electrophysiology. Conventional patch-clamp electrophysiology was used to measure whole cell K DR currents in isolated cerebral myocytes as described previously (18) . Recording electrodes (resistance of 4 -7 M⍀) were fashioned from borosilicate glass, covered in sticky wax to reduce capacitance, and backfilled with pipette solution containing (in mM) 110 potassium gluconate, 30 KCl, 0.5 MgCl 2, 5 HEPES, 10 EGTA, 5 Na2ATP, and 1 GTP (pH 7.2). To attain whole cell configuration, a pipette was lowered onto an isolated smooth muscle cell, and negative pressure was applied to rupture the membrane and achieve a gigaohm seal. Cells were voltage clamped (Ϫ60 mV) in a bath solution containing (in mM) 120 NaCl, 3 NaHCO3, 4. (20 -22°C) .
Experimental protocol and isolated smooth muscle cells. Voltageclamped cells were equilibrated for 15 min before experimentation. Whole cell K DR currents were monitored under control conditions, in the presence of UTP, and in response to increased concentrations of 4-AP. To implicate RhoA in UTP-mediated suppression, C3 exoenzyme was dialyzed into the cell before we measured the effect of UTP. To ascertain the effects of PKA and PKG signaling, myocytes were preincubated in dibutyryl-cAMP (db-cAMP; 2 ϫ 10 Ϫ4 M), forskolin (1 ϫ 10 Ϫ6 M), dibutyryl-cGMP (db-cGMP; 1 ϫ 10 Ϫ4 M), sodium nitroprusside (SNP; 2 ϫ 10 Ϫ5 M), or nitric oxide before the addition of UTP. In general, the net current-voltage relationship was determined by measuring the peak current at the end of a 300-ms pulse to voltages from Ϫ70 to ϩ40 mV. After each pulse, a voltage step to Ϫ40 mV was used to monitor tail currents for the assessment of steady-state activation. Tail currents were calculated as the difference between the peak amplitude of the tail and the sustained level of Intact cerebral arteries. Cerebral artery segments (ϳ2 mm in length) were mounted in a customized arteriograph chamber (J.B. Pierce Laboratory, New Haven, CT) and superfused with warm (37°C) physiological salt solution (pH 7.4) containing (in mM) 119 NaCl, 4.7 KCl, 20 NaHCO 3, 1.7 KH2PO4, 1.2 MgSO4, 1.6 CaCl2, and 10 glucose. Endothelial cells were removed from all arteries by passing air bubbles through the lumen of the vessel, the success of which was confirmed by the loss of bradykinin-induced dilations. Arteries were maintained under no flow conditions and at low intraluminal pressure (15 mmHg) so that agonist responses could be examined independent of myogenic mechanisms. Arterial diameter was monitored with an automated edge detection system (IonOptix, Milton, MA). Smooth muscle E m was assessed by inserting a glass microelectrode (tip resistance ϭ 120 -150 M⍀) filled with 1 M KCl carefully into the vessel wall and recording the voltage difference across the membrane with an intracellular electrometer (Warner Instruments, Hamden, CT). The criteria for successful cell impalement included 1) a sharp negative E m deflection upon entry, 2) a stable recording for at least 1 min after entry, and 3) a sharp return to baseline upon electrode removal. Because Em recordings were typically limited to 3-10 min, a separate impalement was required to measure Em under each experimental condition.
Experimental protocol and intact cerebral arteries. Cerebral arteries were equilibrated for 60 min at 37°C before experimentation. Contractile ability was assessed by briefly (ϳ10 s) exposing cerebral arteries to a 6 ϫ 10 Ϫ2 M KCl challenge. Changes in arterial diameter and smooth muscle Em were measured under control conditions, in response to UTP and in the presence of forskolin (1 ϫ 10 Ϫ6 M) or SNP (2 ϫ 10 Ϫ4 M). Constriction to 4-AP (5 ϫ 10 Ϫ3 M) was also used as a functional index of KDR channel activity in cerebral arteries exposed to UTP alone or in combination with forskolin or SNP.
Chemicals, drugs, and enzymes. Buffer reagents, collagenases (types F and H), UTP, 4-AP, and SNP were obtained from Sigma (St. Louis, MO). Papain was acquired from Worthington (Lakewood, NJ). C3 exoenzyme, db-cAMP, db-cGMP, and forskolin were purchased from Calbiochem (La Jolla, CA). C3 exoenzyme was dissolved in DMSO with a final solvent concentration Յ0.05%. Nitric oxide stock solution (1.9 mM) was made up by saturating deoxygenated ultra-pure water with nitric oxide gas.
Statistical analysis. Data are expressed as means Ϯ SE, and n indicates the number of vessels or cells. Paired t-tests were performed to statistically compare the effects of a given condition or treatment on arterial diameter, E m, or whole cell current. If more than two conditions or treatments were being compared, a repeated-measures ANOVA was used. When appropriate, a Tukey-Kramer pairwise comparison was used for post hoc analysis. P values Յ0.05 were considered statistically significant.
RESULTS
K DR current in isolated cerebral smooth muscle cells. Using conventional whole cell patch-clamp electrophysiology and a pipette solution that minimizes BK Ca channel activity, we identified the K DR current in smooth muscle cells isolated from rat cerebral arteries. Figure 1A shows a typical K DR current where voltage steps positive to Ϫ40 mV elicited activation without noticeable inactivation. To examine the voltage dependence of steady-state activation, tail currents (at Ϫ40 mV) were monitored before deactivation as an indication of the proportion of channels open after a given test pulse. As evident in the normalized data, activation occurred at voltages positive to Ϫ40 mV and was near maximal at ϩ30 mV (Fig. 1A, right) . Fitting the data to a Boltzmann function established a voltage for half-maximal activation of Ϫ0.56 Ϯ 0.66 mV, consistent with what we have previously found for the cerebral arterial K DR current (18) . The K DR current in cerebral smooth muscle is composed of 4-AP-sensitive and insensitive components (18, 23) . We examined 4-AP sensitivity and found the K DR current was reduced in a concentration-dependent manner; this inhibition could be readily washed out (Fig. 1B) . In general, 4-AP initiated a substantial block at micromolar concentrations (20.7 Ϯ 2.7% with 300 M 4-AP at ϩ40 mV), with this effect increasing at millimolar concentrations (26.5 Ϯ 2.4, 34.0 Ϯ 2.9, and 40.8 Ϯ 3.8% at 1, 3, and 10 mM 4-AP, respectively). This study did not observe a voltage dependence to the 4-AP block as assessed at 0, ϩ20, and ϩ40 mV (data not shown).
Because RhoA is hypothesized to be a target of PKA and PKG, we sought to emphasize our previous finding that UTP suppresses the cerebral arterial K DR current through a RhoA signaling pathway (18) . As shown in Fig. 2A , a UTP concentration (3.0 ϫ 10 Ϫ5 M) that elicits a near-maximal constriction (18) suppressed the K DR current, causing a 36.8 Ϯ 4.1% inhibition at ϩ40 mV ( Fig. 2A, right) . Consistent with the view that RhoA activity is a requisite for UTP modulation, C3 exoenzyme (10 mg/ml) eliminated current suppression (Fig. 2B) . As evident in the summary data, there was no detectable change in the net current-voltage relationship after the addition of UTP to cells pretreated with C3 exoenzyme (Fig. 2B, right) .
Regulation of K DR current by PKA and PKG. Because past studies have indicated that PKA and PKG can phosphorylate and inactivate RhoA (6, 17, 19, 24, 26) , this study tested whether activation of the PKA and PKG pathways can influence the ability of RhoA to suppress the K DR current. As shown in Fig. 3 , agents that directly (db-cAMP, 2 ϫ 10 Ϫ4 M) or indirectly (forskolin, 1 ϫ 10 Ϫ6 M) activate PKA did not alter the K DR current under control conditions. They did, however, prevent UTP from suppressing this conductance. In a similar manner, agents that stimulate PKG either reduced (db-cGMP, from 36.8 Ϯ 4.1% to 17.0 Ϯ 3.3% at ϩ40 mV) or abolished (SNP, 2 ϫ 10 Ϫ5 M) the UTP-induced suppression without effect on basal current (Fig. 4) . Nitric oxide (1 ϫ 10 Ϫ7 M), the endogenous activator of guanylate cyclase, also prevented UTP from suppressing the K DR current (Fig. 5) .
Vasomotor and E m measurements of intact cerebral arteries. The preceding findings indicate that PKA and PKG pathways should attenuate UTP-induced constriction by limiting the depolarization of vascular smooth muscle. To test this supposition, this study examined the ability of PKA and PKG activators to dilate and hyperpolarize UTP-constricted arteries. As evident in Fig. 6A , UTP induced a concentration-dependent constriction in cerebral arteries stripped of endothelium and maintained at low pressure (15 mmHg). Preincubation with 1 ϫ 10 Ϫ6 M forskolin attenuated the constrictor response, as evident by a significant rightward shift in vessel sensitivity to UTP (Fig. 6B) . UTP (1 ϫ 10 Ϫ5 M) depolarized cerebral arteries from a resting E m of Ϫ50.1 Ϯ 2.6 to Ϫ34.4 Ϯ 1.6 mV (Fig. 6, C and D) . The addition of forskolin partially reversed this response, with arteries hyperpolarizing from Ϫ36.6 Ϯ 1.2 to Ϫ43.8 Ϯ 1.9 mV. Similar to PKA activation, activation of PKG by SNP attenuated UTP-induced constriction (Fig. 7, A and B) . In addition, SNP partially reversed UTP-induced depolarization, with E m shifting from Ϫ36.3 Ϯ 1.8 to Ϫ41.1 Ϯ 1.0 mV (Fig. 7, C and D) . These latter effects were induced with an SNP concentration 10-fold above that used in patch-clamp experiments. We attribute this discrepancy to the labile nature of this nitric oxide donor in bicarbonate-buffered solutions.
K V channel modulation in intact cerebral arteries. In theory, the reversal of UTP-induced depolarization by PKA and PKG activators could result from a reduction in inward current and/or an increase in outward current. To more directly implicate the K DR current, the constrictor response to 4-AP (5 ϫ 10 Ϫ3 M) was used as a functional assay of channel activity. As illustrated in Fig. 8A , cerebral arteries were first submaximally constricted to UTP. 4-AP was subsequently added to the superfusate to elicit a further constriction (Fig. 8, B and C, left) , the magnitude of which should reflect the proportion of 4-APsensitive K DR channels that remain active and not inhibited by UTP. The addition of forskolin or SNP to the superfusate attenuated UTP-induced constriction. More importantly, the 4-AP-induced constriction was noticeably larger in the presence of these indirect kinase activators, a result indicative of increased K DR channel activity. This difference in the 4-AP response is emphasized in Fig. 8, B and C, right. Note that arteries exposed to both UTP and 4-AP were not maximally constricted because the addition of 6 ϫ 10 Ϫ3 M extracellular K ϩ elicited a further reduction in arterial diameter.
DISCUSSION
This study tested whether the PKA and PKG pathways prevent RhoA from inhibiting K DR channels and thus limit the ability of vasoconstrictors to depolarize and constrict cerebral arteries. Electrophysiological experiments confirmed the presence of a cerebral arterial K DR current that was suppressed by UTP through a RhoA-dependent mechanism. Without changing baseline channel activity, PKA and PKG activators attenuated the ability of UTP to inhibit the K DR current. Pressure myography revealed that PKA and PKG activators hyperpolarized and dilated UTP-constricted arteries, a response that could be partly ascribed to increased activity of 4-AP-sensitive K DR channels. Cumulatively, our findings indicate that PKA and PKG pathways can antagonize agonist-induced constriction and do so in part by limiting RhoA-mediated suppression of the K DR current and the depolarization of cerebral resistance arteries.
K DR current in cerebral arterial smooth muscle. Conventional whole cell patch-clamp electrophysiology was used to characterize the K DR current in smooth muscle cells isolated from cerebral arteries. Similar to past studies from the cerebral and mesenteric circulation, the K DR current displayed measurable activity at voltages positive to Ϫ40 mV and a voltage dependence of half-maximal activation of Ϫ0.56 Ϯ 0.66 mV (Fig. 1) . Although small in magnitude (ϳ1-2 pA between Ϫ60 and Ϫ30 mV), the high-input resistance of vascular smooth muscle cells (5-20 G⍀) ensures that this current will play an important role in controlling E m (5, 20) . Our cerebral arterial K DR currents displayed a sensitivity to 4-AP that is characteristic of vascular K DR . In particular, a 15-20% reduction was observed at 4-AP concentrations (100 -300 M) thought to be specific for Kv1 channel block. As documented in the mesenteric artery (22) , millimolar 4-AP was required to elicit a more substantial block (ϳ34%) in cerebral arterial smooth muscle cells. The presence of a sizable 4-AP-resistant outward current indicates that a second population of K DR channels may be present in cerebral and mesenteric arteries. Although their molecular composition is speculative, potential candidates include Kv2 (3) and Kv7 (21) subfamily members.
PKA and PKG pathways and the K DR current. Past studies have shown that PKA and PKG can phosphorylate membranebound RhoA and inactive this key signaling protein (6, 17, 19, 24, 26) . This process prevents RhoA from interacting with Rho kinase and is thus thought to relax smooth muscle by limiting Ca 2ϩ sensitization (19, 24) . From these observations and those indicating that active RhoA can modulate the 4-AP-sensitive K DR current, we hypothesized that PKA and PKG pathways limit the ability of vasoconstrictors to inhibit the cerebral arterial K DR current. In initiating this examination, we first confirmed that UTP suppresses the K DR current and that this modulation was limited by C3 exoenzyme, an inhibitor of RhoA signaling (Fig. 2) . As previously observed (18) , current suppression peaked 15-20 min after UTP application, with the slow time course likely reflecting the cumulative effects of enzymatic isolation, room temperature recording conditions, and intracellular dialysis by the patch pipette. Stimulating PKA and PKG with either nonhydrolyzable cyclic nucleotide analogs or upstream cyclase activators effectively abolished K DR current inhibition by UTP (Figs. 3-5) . Intriguingly, basal K DR current amplitude was unaffected by the presence of PKA and PKG activators, indicating that the underlying channels are not directly targeted for phosphorylation. These finding differ somewhat from rabbit portal vein and mesenteric artery, where K DR currents were dramatically enhanced with PKA activation (1, 15) . Whether these disparities reflect tissue-specific differences in kinase localization or perhaps unique K DR channels with distinct regulatory capacities awaits further investigation. Although our electrophysiological examination indicates that PKA and PKG pathways regulate K DR by attenuating the suppressive effects of Rho signaling, it does not directly implicate RhoA as the target of phosphorylation. Indeed, one could argue that it is other proteins within the Rho signaling cascade that are phosphorylated. Resolution of this issue awaits more in-depth biochemical and molecular analyses.
PKA and PKG pathways and cerebral arterial constriction. Ionic conductances such as the K DR current actively control arterial tone by influencing E m and, consequently, Ca 2ϩ influx through voltage-gated L-type Ca 2ϩ channels. From the preceding electrophysiological observations, one would predict that, in whole arteries, activation of the PKA and PKG pathways should attenuate agonist-induced depolarization and constriction. In keeping with this prediction, pressure myography revealed that forskolin and SNP limited UTP-induced vasoconstriction and partially reversed the associated depolarization (Figs. 6 and 7) . Although supportive, these functional results do not directly implicate a role for 4-AP-sensitive K DR channels in the hyperpolarizing response. Indeed, given the known sensitivity of smooth muscle K ϩ conductances to PKA and PKG activators, one could rationalize that the preceding reversal simply arose from the activation of large-conductance Ca 2ϩ -activated (2, 7, 33) or ATP-sensitive K ϩ channels (13, 14, 27) . To directly implicate a role for the 4-AP-sensitive K DR current in the attenuation of agonist-induced depolarization, experiments were devised in which the constriction to millimolar 4-AP was used as a functional marker of channel activity. Consistent with a role for K DR channels, 4-AP-induced responses were markedly greater in UTP-constricted vessels following forskolin and SNP application (Fig. 8) . This increased 4-AP effect occurred despite the hyperpolarization Fig. 9 . A schematic of the proposed signaling mechanism by which PKA and PKG pathways prevent KDR current suppression and limit constriction in cerebral arteries. Receptors coupled to G12/13 activate RhoA/Rho kinase to suppress the KDR current, thereby facilitating depolarization and constriction. We propose that the PKA and PKG pathways indirectly modulate KDR by attenuating RhoA signaling, rather than by direct channel regulation. G12/13, trimeric G protein; GEF, guanine nucleotide exchange factor; Rho-K, Rho kinase; AC, adenylate cyclase; sGC, soluble guanylate cyclase.
induced by forskolin and SNP (Fig. 7C) , which reduces K DR channel open probability and the chemical driving force for K ϩ . These functional observations provide compelling evidence that the PKA and PKG pathways can limit agonistinduced constriction and depolarization in part by attenuating RhoA signaling and the inhibition of 4-AP-sensitive K DR channels (Fig. 9) . It is important to consider that, although previous reports indicate that RhoA is likely targeted by PKA and PKG in smooth muscle (19, 24) , our findings do not exclude the possibility that the cyclic nucleotides are directly regulating RhoA signaling in the cerebral circulation.
Physiological implications. A network of resistance arteries controls the magnitude and distribution of blood flow to cerebral tissue. Under dynamic conditions, tone within this network is regulated by multiple stimuli produced by changes in metabolism (11), neural activity (28), blood flow (8) , and intravascular pressure (12, 16) . Although cerebral tone varies under physiological conditions, dramatic alterations in perfusion would have a deleterious impact on cerebral function. It is within this context that one could suggest that the preceding mechanism of K DR regulation ensures that vasoconstrictors do not overly constrict cerebral arteries and thus impair organ perfusion. The relative importance of this mechanism would, however, depend on the endogenous levels of PKA and PKG pathway activators. Agonists likely to be susceptible to such regulation include both pyrimidine and purine nucleotides (activators of P 2Y receptors) as well as thromboxane, all of which activate RhoA signaling (18, 25) . Furthermore, it could be suggested that one means by which reduced endothelial nitric oxide synthase activity elevates cerebral tone during hypertension is through the loss of PKG signaling and its ability to impair K DR inhibition and arterial depolarization.
In summary, this study demonstrated that activation of the PKA and PKG pathways prevents RhoA signaling from suppressing the cerebral arterial K DR current. Importantly, this attenuation limited the ability of UTP to depolarize and constrict intact cerebral arteries. We propose that, under dynamic conditions, this newly described regulatory mechanism would prevent vasoconstrictors from overly constricting cerebral arteries and impairing tissue blood flow.
